Xenon Pharmaceuticals (XENE) EBITDA Margin (2013 - 2025)

Xenon Pharmaceuticals (XENE) posted quarterly EBITDA Margin of 969.84% for Q1 2025, up 96.64% quarter-over-quarter from 28884.85% in Q3 2022.

Xenon Pharmaceuticals (XENE) EBITDA Margin (2013 - 2025) Analysis & Trends

Xenon Pharmaceuticals (XENE) has reported EBITDA Margin for 10 consecutive years, with 969.84% the latest figure, recorded in Q1 2025.

In Q1 2025, EBITDA Margin changed N/A year-over-year to 969.84%; the TTM figure through Dec 2025 stood at 4974.27% (changed N/A YoY), while the FY2025 annual figure was 4974.27%, changed N/A from the prior year.
EBITDA Margin rose to 969.84% in Q1 2025 per XENE's latest filing, from 28884.85% in the prior quarter.
Across five years, EBITDA Margin topped out at 192.0% in Q3 2021 and bottomed at 28884.85% in Q3 2022.
Historically, EBITDA Margin has averaged 4743.51% across 3 years, with a median of 817.25% in 2021.
On a YoY basis, EBITDA Margin climbed as much as 17035 bps in 2022 and fell as far as 2869285 bps in 2022.
Xenon Pharmaceuticals' EBITDA Margin stood at 664.65% in 2021, then sank by 4246 bps to 28884.85% in 2022, then soared by 97 bps to 969.84% in 2025.
Business Quant data shows XENE's EBITDA Margin at 969.84% in Q1 2025, 28884.85% in Q3 2022, and 5655.78% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Xenon Pharmaceuticals	6.03 Bn	6.03 Bn	-	-

Download Data